This page contains brief information about lisocabtagene maraleucel and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.
FDA label information for this drug is available at DailyMed.
Use in Cancer
Lisocabtagene maraleucel is approved to treat:
- B-cell non-Hodgkin lymphoma (NHL), including the following types:
- Diffuse large B-cell lymphoma (DLBCL).
- High-grade B-cell lymphoma.
- Primary mediastinal large B-cell lymphoma.
- Follicular lymphoma grade 3B.
It is used in adults whose cancer relapsed (came back) or did not get better after first-line chemoimmunotherapy or after two or more lines of systemic therapy.
Lisocabtagene maraleucel is only available as part of a special program called Breyanzi REMS (Risk Evaluation and Mitigation Strategies).
Lisocabtagene maraleucel is also being studied in the treatment of other types of cancer.
More About Lisocabtagene Maraleucel
Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.
MedlinePlus Information on Lisocabtagene Maraleucel - A lay language summary of important information about this drug that may include the following:
- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.
Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.
Research Results and Related Resources
Should CAR T Cells Be Used Earlier in People with Non-Hodgkin Lymphoma?
Clinical Trials Accepting Patients
Find Clinical Trials for Lisocabtagene Maraleucel - Check for trials from NCI's list of cancer clinical trials now accepting patients.